Crisis Of Low Supply, High Demand Means Big Opportunity
Right now helium is one of world's best investments. It's Earth's most nonrenewable resource and it's fast running out. That's a crisis because helium is a critical in medical diagnostics, military weapons, and semiconductors, which are the chips that run all the 21st century's gadgets, appliances, and vehicles.
Get a free report that shows you how its supply
Fabrice Egros, insider at Syndax Pharmaceuticals
Fabrice Egros Insider Alerts

Get notified the next time Fabrice Egros buys or sells Syndax Pharmaceuticals stock. Enter your email address below to get our daily insider buying and selling report.

Fabrice Egros Insider Information

Fabrice Egros, Ph.D. has served as a member of our board of directors since September 2013. Since April 2020, Dr. Egros has served as President, Growth Markets of Lupin Limited, an Indian publicly traded pharmaceutical company, where he previously served since October 2015 as President, Asia Pacific and Japan. From November 2012 to September 2015, Dr. Egros served as the Deputy Chief Executive Officer/Chief Operating Officer of NovaMedica LLC, a privately held pharmaceutical company, and was its Chief Operating Officer and a member of its board of directors from July 2012 to September 2015. From February 2011 to July 2012, Dr. Egros served as the Chief Operating Officer of Xanodyne Pharmaceuticals, Inc., a privately held pharmaceutical company. From September 2009 to February 2011, he served as the Senior Vice President, Corporate Business Development and Strategy of UCB, S.A., a publicly traded biopharmaceutical company. Prior to that, Dr. Egros served as the President of UCB, Inc. and of UCB Japan Co. Ltd., each a subsidiary of UCB, S.A. Prior to joining UCB, Dr. Egros held various management and executive positions at Parke-Davis, Warner Lambert Company, a privately held pharmaceutical company, and Sanofi, formerly known as Sanofi-Aventis, a publicly traded pharmaceutical company. Dr. Egros received a B.S. in Pharmacokinetics and Metabolism and a Pharm.D. and Ph.D. in Pharmaceutical Sciences from Chatenay Malabry University, and has participated in the Advanced Management Program at Harvard University.

How do I contact Fabrice Egros?

The corporate mailing address for Mr. Egros and other Syndax Pharmaceuticals executives is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. Syndax Pharmaceuticals can also be reached via phone at (781) 419-1400 and via email at [email protected]

Has Fabrice Egros been buying or selling shares of Syndax Pharmaceuticals?

During the last quarter, Fabrice Egros has sold $252,961.00 in shares of Syndax Pharmaceuticals stock. Most recently, Fabrice Egros sold 14,030 shares of the business's stock in a transaction on Thursday, November 18th. The shares were sold at an average price of $18.03, for a transaction totalling $252,960.90.

Who are Syndax Pharmaceuticals' active insiders?

Syndax Pharmaceuticals' insider roster includes Fabrice Egros (Director), Michael Metzger (COO), Michael Meyers (SVP), Briggs Morrison (CEO), and Dennis Podlesak (Director).

Are insiders buying or selling shares of Syndax Pharmaceuticals?

In the last year, Syndax Pharmaceuticals insiders bought shares 2 times. They purchased a total of 14,467 shares worth more than $204,804.37. In the last year, insiders at the sold shares 8 times. They sold a total of 186,900 shares worth more than $3,686,551.76. The most recent insider tranaction occured on November, 18th when Director Fabrice Egros sold 14,030 shares worth more than $252,960.90. Insiders at Syndax Pharmaceuticals own 7.6 % of the company.

Information on this page was last updated on 11/18/2021.

Fabrice Egros Insider Trading History at Syndax Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/18/2021Sell14,030$18.03$252,960.90View SEC Filing Icon  
See Full Table

Fabrice Egros Buying and Selling Activity at Syndax Pharmaceuticals

This chart shows Fabrice Egros's buying and selling at Syndax Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Syndax Pharmaceuticals Company Overview

Syndax Pharmaceuticals logo
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
Read More

Today's Range

Now: $15.85
Low: $15.64
High: $16.91

50 Day Range

MA: $18.28
Low: $15.85
High: $20.24

2 Week Range

Now: $15.85
Low: $13.02
High: $27.85

Volume

372,992 shs

Average Volume

635,144 shs

Market Capitalization

$782.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.41
Crisis Of Low Supply, High Demand Means Big Opportunity
Right now helium is one of world's best investments. It's Earth's most nonrenewable resource and it's fast running out. That's a crisis because helium is a critical in medical diagnostics, military weapons, and semiconductors, which are the chips that run all the 21st century's gadgets, appliances, and vehicles.
Get a free report that shows you how its supply